Role of neutrophils in persistent airway obstruction due to refractory asthma

Respirology

Volumn 17, Issue 2, 2012, Pages 322-329

  Choi, Jae Sung ^a   Jang, An Soo ^b   Park, Jong Sook ^b   Park, Sung Woo ^b   Paik, Sang Hyun ^a   Park, Jai Soung ^a   Uh, Soo Taek ^a   Kim, Yong Hoon ^a   Park, Choon Sik ^b  

^a Soonchunhyang University   (South Korea)

^b Division of Allergy and Respiratory Medicine   (South Korea)

Author keywords

chronic airflow obstruction; neutrophil; refractory asthma; sputum

Indexed keywords

BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CELL COUNT; CHRONIC DISEASE; DISEASE DURATION; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN CELL; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PERSISTENT AIRWAY OBSTRUCTION; PRIORITY JOURNAL; REFRACTORY ASTHMA; SMOKING; SPUTUM ANALYSIS;

AIRWAY OBSTRUCTION; ASTHMA; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPIROMETRY; SPUTUM; TIME FACTORS;

EID: 84863011547     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.02097.x     Document Type: Article

References (41)

1. Green RH, Brightling CE, Bradding P,. The reclassification of asthma based on subphenotypes. Curr. Opin. Allergy Clin. Immunol. 2007; 7: 43-50. (Pubitemid 46095885)
2. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am. J. Respir. Crit. Care Med. 2000; 162: 2341-51.
3. Wenzel SE,. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368: 804-13. (Pubitemid 44279058)
4. Haldar P, Pavord ID, Shaw DE, et al,. Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med. 2008; 178: 218-24.
5. Ayres JG, Miles JF, Barnes PJ,. Brittle asthma. Thorax 1998; 53: 315-21. (Pubitemid 28215795)
6. Wardlaw AJ, Dunnette S, Gleich GJ, et al,. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma: relationship to bronchial hyperreactivity. Am. Rev. Respir. Dis. 1988; 137: 62-9. (Pubitemid 18032827)
7. Djukanovic R, Wilson JW, Britten KM, et al,. Quantitation of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry. Am. Rev. Respir. Dis. 1990; 142: 863-71. (Pubitemid 20344659)
8. Humbert M, Durham SR, Ying S, et al,. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against 'intrinsic' asthma being a distinct immunopathologic entity. Am. J. Respir. Crit. Care Med. 1996; 154: 1497-504. (Pubitemid 26391204)
9. Wenzel SE, Szefler SJ, Leung DYM, et al,. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am. J. Respir. Crit. Care Med. 1997; 156: 737-43. (Pubitemid 27396409)
10. Jatakanon A, Uasuf C, Maziak W, et al,. Neutrophilic inflammation in severe persistent asthma. Am. J. Respir. Crit. Care Med. 1999; 160: 1532-9.
11. Wenzel SE, Schwartz LB, Langmack EL, et al,. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am. J. Respir. Crit. Care Med. 1999; 160: 1001-8. (Pubitemid 29442043)
12. Sur S, Crotty TB, Kephart GM, et al,. Sudden-onset fatal asthma - a distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am. Rev. Respir. Dis. 1993; 148: 713-19. (Pubitemid 23263785)
13. Fahy JV,. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc. Am. Thorac. Soc. 2009; 6: 256-9.
14. Bumbacea D, Campbell D, Nguyen L, et al,. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur. Respir. J. 2004; 24: 122-8. (Pubitemid 39029077)
15. Kaminska M, Foley S, Maghni K, et al,. Airway remodeling in subjects with severe asthma with or without chronic persistent airflow obstruction. J. Allergy Clin. Immunol. 2009; 124: 45-51.
16. Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. NHLBI/WHO Workshop Report. National Institutes of Health, National Heart, Lung, and Blood Institute, NIH publication no. 95-3659. Bethesda, MD, 1995.
17. Lee YM, Park JS, Hwang JH, et al,. High-resolution CT findings in patients with near-fatal asthma: comparison of patients with mild-to-severe asthma and normal control subjects and changes in airway abnormalities following steroid treatment. Chest 2004; 126: 1840-8.
18. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics - 2002. J. Allergy Clin. Immunol. 2002; 110 (5 Suppl.): 141S-219S.
19. Park SW, Lee YM, Jang AS, et al,. Development of chronic airway obstruction in patients with eosinophilic bronchitis: a prospective follow-up study. Chest 2004; 125: 1998-2004. (Pubitemid 38788162)
20. Simpson JL, Scott R, Boyle MJ, et al,. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006; 11: 54-61.
21. Pavord ID, Brightling CE, Woltmann G, et al,. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999; 353: 2213-14. (Pubitemid 29295261)
22. ten Brinke A, Zwinderman AH, Sterk PJ, et al,. Factors associated with persistent airflow limitation in severe asthma. Am. J. Respir. Crit. Care Med. 2001; 164: 744-8. (Pubitemid 32881907)
23. Contoli M, Baraldo S, Marku B, et al,. Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up. J. Allergy Clin. Immunol. 2010; 125: 830-7.
24. Leung DY, Martin RJ, Szefler SJ, et al,. Dysregulation of interleukin-4, interleukin-5, and interferon gamma gene expression in steroid-resistant asthma. J. Exp. Med. 1995; 181: 33-40.
25. Sher E, Leung DY, Surs W, et al,. Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J. Clin. Invest. 1994; 93: 33-9.
26. Spahn JD, Leung DY, Surs W, et al,. Reduced glucocorticoid binding affinity in asthma is related to ongoing allergic inflammation. Am. J. Respir. Crit. Care Med. 1995; 151: 1709-14.
27. Cho SH, Seo JY, Choi DC, et al,. Pathological changes according to the severity of asthma. Clin. Exp. Allergy 1996; 26: 1210-19. (Pubitemid 26354372)
28. Chetta A, Foresi A, Donno MD, et al,. Airway remodeling is a distinctive feature of asthma and is related to severity of asthma. Chest 1997; 111: 852-7. (Pubitemid 27171451)
29. Peat JK, Woolcock AJ, Collen K,. Rate of decline of lung function in subjects with asthma. Eur. J. Respir. Dis. 1987; 70: 171-9. (Pubitemid 17029522)
30. Brown PJ, Greville HW, Finucane KE,. Asthma and irreversible airflow limitation. Thorax 1984; 39: 131-6.
31. Agertoft L, Pedersen S,. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir. Med. 1994; 88: 373-81. (Pubitemid 24167107)
32. Pietinalho A, Pelkonen A, Rytilä P,. Linkage between smoking and asthma. Allergy 2009; 64: 1722-7.
33. Murphy P, Hillman T, Rajakulasingam K,. Therapeutic targets for persistent airway inflammation in refractory asthma. Biomed. Pharmacother. 2010; 64: 140-5.
34. Mauad T, Silva LF, Santos MA, et al,. Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma. Am. J. Respir. Crit. Care Med. 2004; 170: 857-62. (Pubitemid 39346480)
35. Green RH, Brightling CE, McKenna S, et al,. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715-21. (Pubitemid 35447900)
36. Berry M, Morgan A, Shaw DE, et al,. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007; 62: 1043-9. (Pubitemid 350206195)
37. Monteseirín J,. Neutrophils and asthma. J. Investig. Allergol. Clin. Immunol. 2009; 19: 340-54.
38. Cox G,. Glucocorticoid treatment inhibits apoptosis in human neutrophils: separation of survival and activation outcomes. J. Immunol. 1995; 154: 4719-25.
39. Pham DN, Chu HW, Martin RJ, et al,. Increased matrix metalloproteinase-9 with elastolysis in nocturnal asthma. Ann. Allergy Asthma Immunol. 2003; 90: 72-8. (Pubitemid 36553819)
40. Jang AS, Choi IS, Koh YI, et al,. Volatile organic compounds contribute to airway hyperresponsiveness. Korean J. Intern. Med. 2007; 22: 8-12.
41. Holgate ST,. A brief history of asthma and its mechanisms to modern concepts of disease pathogenesis. Allergy Asthma Immunol. Res. 2010; 2: 165-71.